Related Experiment Video
Updated: May 22, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Rational management of differentiated thyroid cancer
Birendra Kishore Das1, Biswa Mohan Biswal, Venkata Murali Krishna Bhavaraju
1Visiting Professor, Department of Nuclear Medicine, Radiotherapy and Oncology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
The Malaysian Journal of Medical Sciences : MJMS
|May 17, 2012
Summary
Differentiated thyroid cancer (DTC) is rare but treatable, with over 90% survival. This review proposes a management protocol to improve care, especially in iodine-deficient regions, addressing physician awareness and treatment strategies.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Differentiated thyroid cancer (DTC) has a low incidence (approx. 1%) but higher rates in iodine-deficient areas of Southeast Asia.
- DTC is highly curable with a >90% survival rate, and its progression can be managed for years with radioiodine therapy.
- Limited physician experience due to low incidence can lead to suboptimal management, increasing morbidity and mortality.
Purpose of the Study:
- To develop a rational management protocol for differentiated thyroid cancer (DTC).
- To enhance physician awareness regarding appropriate DTC management.
- To guide centers lacking advanced facilities by suggesting referral protocols.
Main Methods:
- Review of current literature and therapeutic approaches for differentiated thyroid cancer.
- Development of a standardized management protocol for DTC.
- Inclusion of recent advancements like recombinant human thyrotropin (rhTSH) and retinoic acid therapy.
Main Results:
- A proposed protocol aims to standardize DTC treatment.
- Emphasis on physician education to improve patient outcomes.
- Integration of new therapeutic options for redifferentiation and treatment.
Conclusions:
- A structured management protocol is crucial for optimizing differentiated thyroid cancer (DTC) treatment outcomes.
- Increased physician awareness and adherence to protocols can significantly reduce DTC-related morbidity and mortality.
- Referral systems and adoption of novel therapies like rhTSH can improve long-term disease control and quality of life.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...